Larsucosterol not checked
Bausch Health Americas, Inc. · Durect · DUR-928 · DV928
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hepatitis
- Main trialPhase 3
- “The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score greater than or equal to (\>=) 32 and Model for End-stage Liver Disease (MELD) scores 21-30, inclusive.”In the company’s words, NCT07428538 on ClinicalTrials.gov
- Other names
- DUR-928 · DV928
Other drugs for Hepatitis
- GST-HG141Fujian Akeylink Biotechnology Co., Ltd. · Phase 3
- AHB-137Ausper Biopharma Co., Ltd. · Phase 3
- Bemnifosbuvir/RuzasvirAtea Pharmaceuticals, Inc. · Phase 3
- ElebsiranVir Biotechnology, Inc. · Phase 3
- TobevibartVir Biotechnology, Inc. · Phase 3
- In-House Recombinant Hepatitis B vaccinePT Bio Farma · Phase 3
Coming up1
- Nov 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Nov 2027 | Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | |
| Phase 2Terminated | 31 Jan 2019 | A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) | |
| Phase 2Completed | 9 Sep 2019 | A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis | |
| Phase 2Completed | 11 Nov 2019 | Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis | |
| Phase 2Terminated | 4 Mar 2021 | DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury | |
| Phase 2Completed | 6 Sep 2023 | A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026